Royalty Pharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Royalty Pharma (NASDAQ:RPRX) Full Year 2024 Results

Key Financial Results

• Revenue: US$2.26b (down 3.9% from FY 2023).
• Net income: US$859.0m (down 24% from FY 2023).
• Profit margin: 38% (down from 48% in FY 2023). The decrease in margin was primarily driven by higher expenses.
• EPS: US$1.93 (down from US$2.54 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Royalty Pharma EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 16%. Earnings per share (EPS) exceeded analyst estimates by 1.4%.

Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 3.2% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Royalty Pharma you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.